Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Greyledge Technologies
AddedFeb 16, 2024
UpdatedJun 18, 2026
Greyledge Technologies

Greyledge Technologies

Greyledge develops advanced quality control systems for processing biologic therapy products, enhancing scientific understanding and product optimization.

HQ
Lone Tree, CO, US
Founded
2010
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to refine cellular medicine through biodata analytics, Greyledge Technologies specializes in autologous cell therapeutics, including Platelet Rich Plasma (PRP) and Bone Marrow Concentrate (BMC). The company develops advanced quality control systems to process biologic therapy products derived from a patient’s own blood or bone marrow tissue. This innovative approach allows for precise measurement and quantification of complex cell populations, enabling customized treatments tailored to individual patients and specific clinical applications.

Greyledge Technologies has garnered trust from leading medical professionals and institutions due to its pioneering methods in biodata analytics and product optimization. Notable achievements include significant advancements in the scientific understanding of cell-based therapies and their applications in treating orthopedic conditions. By combining detailed product analytics with patient-reported outcomes, Greyledge has made a substantial impact on the field of cellular medicine, setting new standards for quality and efficacy in biologic therapies.

Greyledge Technologies - Quick Facts

When was Greyledge Technologies founded?

Greyledge Technologies was founded in 2010.

Where is Greyledge Technologies' headquarters located?

Greyledge Technologies' headquarters is located in Lone Tree, CO, US.

When was Greyledge Technologies' last funding round?

Greyledge Technologies' most recent funding round was for $4.3M (USD) in April 2022.

How much has Greyledge Technologies raised to-date?

As of Apr 4, 2022, Greyledge Technologies has raised a total of $6.8M (USD).

How many employees does Greyledge Technologies have?

Greyledge Technologies has 18 employees as of Feb 5, 2024.

Greyledge Technologies - Classification

Ownership
  • Private
Technology
  • Analytics
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Biologic Therapy
  • Quality Control
Tags
  • Biotech
  • Data Information
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified